Page 123 - Read Online

Page 336 Jiang et al. J Transl Genet Genom 2021;5:323-40 https://dx.doi.org/10.20517/jtgg.2021.21

sum up, more accurate biomarkers and predictors for the response to treatment and survival are needed.
More effective treatment and the optimal combination of these therapeutic options still need to be explored
in the future according to the development of the above progress and further challenges.

DECLARATIONS
Authors’ contributions
Conception and design: Peng R, Jiang J
Acquisition of data: Jiang J, Ruan Z, Wang Q, Jiang L
Writing, review, and/or revision of the manuscript: Peng R, Jiang J
Administrative, technical, or material support: Ruan Z, Wang Q
Study supervision: Peng R

Availability of data and materials
Not applicable.

Financial support and sponsorship
The work was supported by Guangzhou Science and Technology Plan Project (Grant No. 201804010024).

Conflicts of interest
Not applicable.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. Harabuchi Y, Yamanaka N, Kataura A, Imai S, Kinoshita T, Osato T. Epstein-Barr virus in nasal T-cell lymphomas in patients with
lethal midline granuloma. Lancet 1990;335:128-30. DOI PubMed
2. Aozasa K, Ohsawa M, Tajima K, et al. Nation-wide study of lethal mid-line granuloma in Japan: frequencies of wegener's
granulomatosis, polymorphic reticulosis, malignant lymphoma and other related conditions. Int J Cancer 1989;44:63-6. DOI
PubMed
3. Gaal K, Sun NC, Hernandez AM, Arber DA. Sinonasal NK/T-cell lymphomas in the United States. Am J Surg Pathol 2000;24:1511-
7. DOI PubMed
4. Nagata H, Konno A, Kimura N, et al. Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from
primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus. Blood 2001;97:708-13. DOI PubMed
5. Ko YH, Ree HJ, Kim WS, Choi WH, Moon WS, Kim SW. Clinicopathologic and genotypic study of extranodal nasal-type natural
killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans. Cancer 2000;89:2106-16. DOI PubMed
6. Gualco G, Domeny-Duarte P, Chioato L, Barber G, Natkunam Y, Bacchi CE. Clinicopathologic and molecular features of 122
Brazilian cases of nodal and extranodal NK/T-cell lymphoma, nasal type, with EBV subtyping analysis. Am J Surg Pathol
2011;35:1195-203. DOI PubMed
7. Kaur K, Kakkar A, Bhardwaj N, et al. Spectrum of cytomorphological features of extranodal NK/T-cell lymphoma, nasal type.
Cytopathology 2019;30:393-401. DOI PubMed
8. Huang Y, Chen S, Wei R, et al. CD20-positive extranodal NK/T cell lymphoma: clinicopathologic and prognostic features. Virchows
Arch 2020;477:873-83. DOI PubMed
9. Au WY, Weisenburger DD, Intragumtornchai T, et al; International Peripheral T-Cell Lymphoma Project. Clinical differences
between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell
Lymphoma Project. Blood 2009;113:3931-7. DOI PubMed
10. Nagato T, Ohkuri T, Ohara K, et al. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-
cell lymphoma: a potential rationale for immunotherapy. Cancer Immunol Immunother 2017;66:877-90. DOI PubMed